Product
AFM13
3 clinical trials
1 abstract
7 indications
Indication
Peripheral T Cell LymphomaIndication
Mycosis FungoidesIndication
Hodgkin LymphomaIndication
lymphomaIndication
T cellIndication
CutaneousIndication
Hodgkin lymphomaClinical trial
A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa StudyStatus: Completed, Estimated PCD: 2020-04-01